Antiarrhythmic drug therapy in the neonate.
The neonate presents a challenge for the practitioner considering antiarrhythmic therapy: pharmacokinetics are different than in older children or adults; and the arrhythmia substrate may also differ, with respect to issues of ion channel and autonomic nervous system development. This paper reviews the need for antiarrhythmic drug therapy in the neonate, developmental aspects of pharmacokinetics, autonomic regulation and cellular electrophysiology and the antiarrhythmics available today with an emphasis on newer drug therapy.
Dubin
A
Division of Pediatric Cardiology, Stanford University, 750 Welch Rd., Suite 305, Palo Alto, CA, USA